Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis (ReBUILD)

This study has been completed.
Information provided by (Responsible Party):
University of California, San Francisco Identifier:
First received: January 10, 2014
Last updated: April 14, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2016
  Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)